v3.26.1
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of segment loss, including significant segment expenses
The table below is a summary of the segment loss, including significant segment expenses (in thousands):
Three Months Ended
June 30, 2026		Six Months Ended
June 30, 2026		Three Months Ended June 30, 2025Six Months Ended June 30, 2025
License revenue$— $1,039 $— $— 
Less:
CR-001 external research and development costs6,305 11,384 3,415 9,683 
CR-002 external research and development costs6,111 9,696 3,415 4,480 
Discovery external research and development costs(1)
91 112 556 1,424 
Personnel costs11,243 21,888 9,347 12,437 
Milestone and license fees(2)
— 2,500 855 1,820 
Professional and other fees(3)
4,384 8,322 3,442 5,411 
Other expense (income)(3,297)(4,743)760 1,683 
Net loss and comprehensive loss$(24,837)$(48,120)$(21,790)$(36,938)
_________________________
(1)Discovery external research and discovery costs include costs associated with CR-003 and other candidate discovery activities.
(2)Milestone and license fees include a $2.5 million payment to Paragon related to the first dosing of a human patient in a Phase 1 trial for CR-001 per the CR-001 License Agreement.
(3)Professional and other fees includes professional fees, consulting fees, office and facilities expense, and miscellaneous other expense.